Last Updated: November 9, 2026

CLINICAL TRIALS PROFILE FOR BREXUCABTAGENE AUTOLEUCEL

« Back to Dashboard

All Clinical Trials for brexucabtagene autoleucel

Subscribe to access the full database, or Start Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02601313 ↗	Study to Evaluate the Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma	Active, not recruiting	Kite, A Gilead Company	Phase 2	2015-11-09	The primary objective of the study is to evaluate the efficacy of brexucabtagene autoleucel (KTE-X19) in participants with relapsed/refractory mantle cell lymphoma (MCL)
NCT02614066 ↗	A Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)	Active, not recruiting	Kite, A Gilead Company	Phase 1/Phase 2	2016-03-07	The primary objectives of this study are to determine the safety and efficacy of brexucabtagene autoleucel (KTE-X19) adult participants with relapsed/refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL).
NCT02625480 ↗	Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma	Recruiting	Kite, A Gilead Company	Phase 1/Phase 2	2016-02-01	The primary objectives of this study are to evaluate the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in pediatric and adolescent participants with relapsed/refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL) or relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (NHL).
NCT03624036 ↗	Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma	Active, not recruiting	Kite, A Gilead Company	Phase 1	2018-11-15	The primary objective of this study is to evaluate the safety and tolerability of brexucabtagene autoleucel (KTE-X19) in adults with relapsed/refractory chronic lymphocytic leukemia (r/r CLL) and small lymphocytic lymphoma (r/r SLL).
NCT03642626 ↗	MT2017-45: CAR-T Cell Therapy for Heme Malignancies	Recruiting	Masonic Cancer Center, University of Minnesota		2018-12-18	This is a phase II study of FDA-approved CAR-T products for patients with hematologic malignancies. Patients will be assigned to Arm A and B based on age and diagnosis. Overall remission rate, safety events and other endpoints will be calculated for Arm A and B separately.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for brexucabtagene autoleucel

Condition Name

Chart
Table

Condition Name for brexucabtagene autoleucel
Intervention	Trials
Acute Lymphoblastic Leukemia	3
Mantle Cell Lymphoma	2
Relapsed/Refractory Mantle Cell Lymphoma	2
Lymphoblastic Leukemia	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for brexucabtagene autoleucel
Intervention	Trials
Leukemia, Lymphoid	6
Lymphoma	5
Precursor Cell Lymphoblastic Leukemia-Lymphoma	5
Leukemia	5
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for brexucabtagene autoleucel

Trials by Country

Map
Table

Trials by Country for brexucabtagene autoleucel
Location	Trials
United States	81
France	4
Netherlands	4
Germany	4
Canada	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for brexucabtagene autoleucel
Location	Trials
Florida	7
California	7
Texas	7
Tennessee	5
New York	5
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for brexucabtagene autoleucel

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for brexucabtagene autoleucel
Clinical Trial Phase	Trials
PHASE2	1
PHASE1	1
Phase 2	4
[disabled in preview]	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for brexucabtagene autoleucel
Clinical Trial Phase	Trials
RECRUITING	7
Active, not recruiting	3
Not yet recruiting	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for brexucabtagene autoleucel

Sponsor Name

Chart
Table

Sponsor Name for brexucabtagene autoleucel
Sponsor	Trials
Kite, A Gilead Company	8
M.D. Anderson Cancer Center	2
H. Lee Moffitt Cancer Center and Research Institute	2
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for brexucabtagene autoleucel
Sponsor	Trials
Industry	9
Other	8
UNKNOWN	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.